Latest Articles and Analysis

Rising employer premiums averaging 9.5% erode wages, forcing workers to delay care.

Break Up Big Medicine Act would force structural separation of insurers, PBMs, and pharmacies.

FY2026 preserves HIV funding but level funding can't support long-acting therapeutics or growing needs.

FTC investigation confirms pharmacy benefit managers extracted billions in excess revenue through specialty drug markup schemes.

FTC complaint against major PBMs for anticompetitive rebating and insulin pricing.

Q3 2024 Watch monitoring HCV treatment access across ADAPs, Medicaid, Veterans programs, and assistance initiatives.

How payor cost-containment strategies drive health disparities and limit care access.

PBM practices and supply chain vulnerabilities enable counterfeit drug distribution.

2024 federal healthcare policy priorities: 340B reform, PBM oversight, and telehealth.

Payers face regulatory scrutiny for systematic coverage denials and prior authorization abuse.

Payers use prior authorization and step therapy to deny care, driving health disparities.

Preview of 2023 federal regulatory priorities: Section 1557, IRA implementation, and prior authorization reform.

Innovative HIV medications available but inaccessible: payer barriers block Cabenuva and Apretude access.

AMA survey: 93% of providers say prior authorizations delay care with 91% reporting negative clinical impact.

Biden's SOTU addresses harm reduction, endorses MAT Act; limited HIV-specific programming focus.

Copay accumulator programs block patient assistance from counting toward deductibles; HELP Copays Act needed.

Analyzes the role of contract pharmacies and intermediaries in 340B drug distribution and patient access.

Examines CMS's rebate rule on copay accumulator programs that block patient assistance from counting toward deductibles.